Video 1 October 2014

IFPMA 2014 interview series on ‘The R&D challenges in tackling Ebola’


This IFPMA video interview with Ripley Ballou, who’s in charge of GlaxoSmithKline’s (GSK’s) Ebola vaccine program in Rixensart, Belgium, was recorded soon after Ebola scientists and representatives from companies and regulatory bodies met at the World Health Organization’s (WHO’s) headquarters in Geneva, Switzerland, 4-5 September, to discuss how to speed up clinical development of vaccines, a process that normally takes years. Dr Ripley Ballou, like many public health specialists, believes that vaccines will have an important role to play in stopping the catastrophic outbreak in West Africa, which has so far caused at least 6553 cases and more than 3000 deaths in Guinea, Sierra Leone, and Liberia. (Reported numbers; the real toll is known to be much higher.) (Geneva, 30 September 2014)


The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit

Learn more

Media Contact

Elliot Dunster